NASDAQ: MIRMFoster City, CaliforniaCommercial stage
Mirum Pharmaceuticals
A rare-disease company with four approved medicines, mostly for rare liver conditions. Its late-stage pipeline is led by brelovitug, an antibody for chronic hepatitis delta.
Therapeutic areasRare liver disease · Hepatitis delta · Rare bone disease (FOP) · Fragile X
Marketed medicinesLIVMARLI · Cholbam · Ctexli · Atebrioz (launched Oct 2026)
Lead pipelineBrelovitug (Phase 3, BLA 1H 2027) · Volixibat (PSC, PBC) · MRM-3379
Modality and modelOral small molecules and antibodies · Direct product sales; Takeda partner in Japan
Analyst read
Q2 → Q3 2026In short
Every 2026 date guided in the Q2 update was met. The one open item sits with the FDA.
Clinical delivery
Both brelovitug Phase 3 trials, the Atebrioz FDA decision and the EXPAND readout landed when Q2 said they would.
Commercial momentum
Sales grew again and full-year guidance went up for a second quarter running. Atebrioz launched in October.
Spending and cash
Higher R&D widened the operating loss, but operating cash use stayed small. Cash fell mainly on a note buyback.
The one to watch
Volixibat in PSC: the 1H 2027 filing plan stands, with no word on the FDA's Q2 call for a Phase 3 trial.
Guided next, as of the Q3 filing
Nov 3Q4 2026First quarter of Atebrioz sales
Q1 2027Volixibat VANTAGE Phase 2b topline (PBC)
1H 2027Brelovitug BLA; possible US launch Q4 2027
1H 2027LIVMARLI sNDA · volixibat NDA · Atebrioz sNDA
2H 2027AZURE-2 and AZURE-3 topline
Net product sales and guidance
US$ MFiling or financialGuided in Q2, deliveredNew since Q2Open questionGuided, not yet due
| Program | Q2 2026 view | Q3 2026 view | Date | Status |
|---|
Selected item
click a rowBrelovitug Phase 3 readouts
guided in Q2 · combined endpoint at Week 24How to read the trials
Endpoint. Virologic response plus normal liver enzymes (ALT) at Week 24.
Control. Both AZURE trials used a delayed-treatment arm, not placebo. That arm started treatment at Week 24 in AZURE-1 and Week 12 in AZURE-4.
Drug. Brelovitug is a fully human monoclonal antibody that binds hepatitis B surface antigen, given under the skin weekly or every four weeks.
Next. BLA planned for 1H 2027. AZURE-2 and AZURE-3 topline in 2H 2027.